Evolent Health, Inc (NYSE:EVH) received a $32.00 target price from equities researchers at Leerink Swann in a research report issued to clients and investors on Friday. The brokerage currently has a “buy” rating on the technology company’s stock. Leerink Swann’s price target would indicate a potential upside of 87.68% from the company’s current price.

A number of other equities research analysts also recently commented on the company. J P Morgan Chase & Co reiterated a “buy” rating on shares of Evolent Health in a research report on Friday. BidaskClub downgraded Evolent Health from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. Zacks Investment Research downgraded Evolent Health from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Cowen and Company reiterated an “outperform” rating and set a $33.00 price objective (down previously from $35.00) on shares of Evolent Health in a research report on Wednesday, August 9th. Finally, Robert W. Baird set a $35.00 price objective on Evolent Health and gave the company a “buy” rating in a research report on Tuesday, August 8th. Three analysts have rated the stock with a sell rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $29.90.

Evolent Health (EVH) opened at 17.05 on Friday. The stock’s market cap is $1.12 billion. The firm’s 50-day moving average price is $23.78 and its 200 day moving average price is $22.66. Evolent Health has a 52-week low of $14.50 and a 52-week high of $27.50.

Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Monday, August 7th. The technology company reported ($0.13) EPS for the quarter, meeting analysts’ consensus estimates of ($0.13). Evolent Health had a negative return on equity of 6.44% and a negative net margin of 17.57%. The company had revenue of $107.30 million during the quarter, compared to the consensus estimate of $104.45 million. During the same quarter in the prior year, the firm earned ($0.20) EPS. The company’s quarterly revenue was up 89.9% compared to the same quarter last year. Equities analysts predict that Evolent Health will post ($0.42) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/08/18/evolent-health-inc-evh-pt-set-at-32-00-by-leerink-swann.html.

In other Evolent Health news, Director Kenneth A. Samet sold 4,000 shares of the business’s stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $25.75, for a total transaction of $103,000.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Nicholas Mcgrane sold 10,495 shares of the business’s stock in a transaction on Wednesday, June 7th. The shares were sold at an average price of $26.95, for a total transaction of $282,840.25. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,398,253 shares of company stock worth $113,721,009. Company insiders own 8.79% of the company’s stock.

A number of hedge funds have recently made changes to their positions in EVH. ETF Managers Group LLC purchased a new stake in shares of Evolent Health during the second quarter valued at about $102,000. BNP Paribas Arbitrage SA increased its stake in shares of Evolent Health by 815.4% in the second quarter. BNP Paribas Arbitrage SA now owns 4,751 shares of the technology company’s stock valued at $120,000 after buying an additional 4,232 shares during the period. US Bancorp DE increased its stake in shares of Evolent Health by 0.3% in the first quarter. US Bancorp DE now owns 5,654 shares of the technology company’s stock valued at $126,000 after buying an additional 19 shares during the period. Point72 Asia Hong Kong Ltd purchased a new stake in shares of Evolent Health during the first quarter valued at about $126,000. Finally, Bank of Montreal Can increased its stake in shares of Evolent Health by 4,249.7% in the first quarter. Bank of Montreal Can now owns 6,220 shares of the technology company’s stock valued at $138,000 after buying an additional 6,077 shares during the period. 68.08% of the stock is currently owned by institutional investors.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Analyst Recommendations for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.